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Abstract
Background: LPS-activated macrophages produce mediators which are involved in inflammation and tissue injury,
and especially those associated with endotoxic shock. The non toxic tellurium compound ammonium tri-chloro
(dioxoethylene-O,O’-)tellurate, AS101, has been recently shown to exert profound anti-inflammatory properties in
animal models, associated with its Te(IV) redox chemistry. This study explores the anti-inflammatory properties of
AS101 with respect to modulation of inflammatory cytokines production and regulation of iNOS transcription and
expression in activated macrophages via targeting the NFkB complex.
Results: AS101 decreased production of IL-6 and in parallel down-regulated LPS-induced iNOS expression and NO
secretion by macrophages. AS101 reduced IkB phosphorylation and degradation, and reduced NFkB nuclear
translocalization, albeit these effects were exerted at different kinetics. Chromatin immunoprecipitation assays
showed that AS101 treatment attenuated p50-subunit ability to bind DNA at the NFkB consensus site in the iNOS
promotor following LPS induction.
Conclusions: Besides AS101, the investigation of therapeutic activities of other tellurium(IV) compounds is scarce in
the literature, although tellurium is the fourth most abundant trace element in the human body. Since IKK and
NFkB may be regulated by thiol modifications, we may thus envisage, inview of our integrated results, that Te(IV)
compounds, may have important roles in thiol redox biological activity in the human body and represent a new
class of anti-inflammatory compounds.
Introduction
Inflammation is the central feature of many pathophy-
siological conditions that occur in response to tissue
injury and as part of host defenses against microorgan-
isms. Macrophages are the main proinflammatory cells
responsible for invading pathogens by releasing proin-
flammatory mediators such as IL-6, including the short
lived free radical, NO[1]. During inflammatory pro-
cesses, large amounts of NO generated by the inducible
isoforms of NOS has been suggested to have beneficial
microbicidal, antiviral and antitumoral effects; however,
aberrant iNOS induction is involved in the pathophy-
siology of many human diseases[2]. Additionally, LPS-
induced IL-6 production acts as an endogenous pyrogen
in addition to its multiple effects on the immune system
[3]. NFB is one of the most ubiquitous transcription
f a c t o r sa n df u n c t i o n sa sac e n t r a lp l a y e ri nt h ec h r o n i c
inflammatory diseases development, partly through IL-6
[4,5] and iNOS expression [6-8]. Thus, discovery of inhi-
bitors that preferentially target the binding of NFBt o
its consensus DNA sequence would have important clin-
ical applications. Moreover, NFB activation is tightly
linked with redox regulation since the DNA binding
activity of oxidized NFB is significantly diminished[9].
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any medium, provided the original work is properly cited.NFB is present in the cytoplasm as an active heterotri-
mer consisting of p50, p65 and IkBa subunits. Upon
activation of the complex, phosphorylation and degrada-
tion of IkBa exposes nuclear localization signals on the
p50/p65 complex, leading to nuclear translocation and
binding to specific regulated sequences in the DNA,
thus controlling gene transcription[10].
AS101, a small non toxic organotellurium-IV com-
pound, is a potent immunomodulator (in-vitro and in-
vivo) with a variety of potential therapeutic applications
[11-13]; it is currently being evaluated in PhaseII clinical
trials in cancer patients. Accumulated evidence suggests
that much of the biological activity of organotellurium
compounds is directly related to their specific chemical
interactions with endogenous thiols and may be impor-
tant for manifestation of the biological function itself.
Previously, we clarified several mechanistic aspects of
this chemistry, and discussed its relationship to the bio-
logical activity of AS101[14]. If the reacting thiol is a
cysteine residue, the reaction product may alter the bio-
logical activity of the target protein. The Te(IV)-thiol
chemical bond may lead to conformational change or
disulfide bond formation, possibly resulting in a loss of
the biological activity, if the thiol residue is essential for
that function. Indeed, we demonstrated that AS101 and
other TeIV-compounds specifically inactivate cysteine
proteases [14-16], while exhibiting no effect on the
other families of serine-, aspartic- and metalloproteases,
in good agreement with the predictions of their unique
Te(IV)-thiol chemistry. Furthermore, the proteolytic
activity of the inactivated cysteine proteases could be
restored by reducing agents such as NaBH4, further sup-
porting the suggestion that the inactivation process
involves oxidation of the catalytic thiol to a disulfide
[14]. Because of the Te(IV) valence of AS101, it can
serve as a reducing or oxidizing agent, depending on the
environmental oxidation milieu[17]. Previously we
demonstrated that AS101 exerts anti-inflammatory
effects in different in-vivo models through possible
redox-mechanism with thiols[15,16,18]. In light of the
thiol sensitive regulation of the NFkB pathway, this
study explores if the redox traits of AS101 will enable
its anti-inflammatory effects with respect to its ability to
reduce pro-inflammatory cytokines and inhibit iNOS
expression and NO release in LPS-stimulated
RAW264.7 macrophages by targeting the NFB activa-
tion pathway.
Materials And Methods
Cell Culture and Sample Treatment
The RAW264.7 murine macrophage cell line was grown
at 37°C in DMEM medium supplemented with 10%
FBS, penicillin (100 units/ml), streptomycin sulfate (100
mg/ml), and 1% NEAA in a humidified atmosphere of
5% CO2. Cells were stimulated with LPS (1 μg/ml) in
t h ep r e s e n c eo ra b s e n c eo fA S 1 0 1( 0 . 5 ,2[ μg/ml]), as
indicated for specific experiments.
Reagents
All media components were supplied by Biological
Industries, Kibbutz Beit-Haemek, Israel; LPS (E. coli,
055:B5) (Sigma-Aldrich, Rehovot, Israel); AS101 was
supplied by M. Albeck from the Department of Chemis-
try at Bar-Ilan University, in a solution of PBS, pH 7.4,
and maintained at 4°C.
Protein Isolation and Western Blotting
Cells were suspended with ice-cold lysis buffer contain-
ing 50 mM Tris(pH 7.5), 150 mM NaCl, 10% glycerol,
1% TritonX, 1 mM EDTA, 1 mM PMSF, 0.4 mM
sodium vanadate, 5 mg/ml aprotinin, and 5 mg/ml leu-
peptin for 15 min on ice, and centrifuged at 14000 rpm
for 10 min. Cell lysates were boiled for 5 min, electro-
phoresed on SDS-PAGE, and membranes were incu-
bated with anti-iNOS, anti-IkB, anti-p65 (Santa-Cruz
Biotechnology), anti-pIkB
ser32/36(Cell Signaling) and
actin (Sigma-Aldrich, Rehovot, Israel) antibodies. Blots
were developed using horseradish peroxidase-conjugated
secondary antibodies and the ECL detection system
(Amersham-Pharmacia Biotech).
Nuclear and cytosolic fractions preparation
Cells were suspended and homogenized with ice-cold
lysis buffer containing: 10 mM Hepes (pH 7.4), 1.5 mM
MgCl2, 10 mM KCl, 5 mg/ml aprotinin and 5 mg/ml
leupeptin for 5 min. Suspended cells were centrifuged at
2400 rpm for 15 min, and the supernatants were centri-
fuged for 45 min at 14000 rpm. The cytosolic extracts
were stored at -20°C. The nuclear pellet was resus-
pended and incubated for 45 min in lysis buffer contain-
ing: 20 mM Hepes (ph 7.4), 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 5 mg/ml aprotinin, and 5 mg/ml
leupeptin. The nuclear lysate was centrifuged for 45 min
at 14000 rpm and the fraction containing the soluble
nuclear proteins was kept at -20°C.
NO levels quantification
NO
-
2 was assayed by the Griess reaction, as a measure
of NO production[19].
IL-6 Quantification
IL-6 ELISA kit (R&D Systems, Minneapolis, MN) was
used for the quantitative measurement of this cytokine
in supernatants.
ChIP
The ChIP assay was done using the Upstate-kit (Milli-
pore, USA) according to manufacturer’s instructions.
Briefly, 1 × 10
6/ml RAW 264.7 cells were treated with
LPS (1 μg/ml) and AS101 (2 μg/ml) for 1 h. Formalde-
hyde (1%) was added to the culture medium, and after
incubation for 10 min at 37°C, cells were lysed for 10
min at 4°C and were sonicated eight times for 15 s each.
One third of the lysate was used as DNA input control.
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Chip dilution buffer supplied within the commercial kit
followed by incubation with an anti-p50 Ab or nonspe-
cific control Ab (Santa-Cruz Biotechnology) overnight at
4°C. Immunoprecipitated complexes were collected
using protein A-agarose beads. The precipitates were
extensively washed and then incubated in the elution
buffer (1% SDS and 0.1 M NaHCO3)a tr o o mt e m p e r a -
ture for 15 min. Cross-linking of protein-DNA com-
plexes was reversed at 65°C for 4 h, followed by
treatment with 10 mg/ml proteinase K for 1 h at 45°C.
DNA was extracted with phenol/chloroform and preci-
pitated with ethanol. Pellets were resuspended in TE
buffer and subjected to PCR amplification using NFkB
consensus site specific (forward:CAAGCCAGGGT
ATGTGGTTT; reverse:GCAGCAGCCATCAGGTA
TTT) and non-specific (forward: TTGGCACCATC
TAACCTCAC, reverse:TGGTGTATCCTCATGCAA
GG) primers (Hy-Labs, Israel) in iNOS promoter. The
resulting product was separated by 1% agarose gel
electrophoresis.
Statistical Analysis
Results are expressed as the mean ± S.E. of triplicate
experiments. Statistical significance of values was calcu-
lated using the Student’s t-test. p < 0.05 was considered
statistically significant.
Results
Effect of AS101 on LPS-induced iNOS expression, NO
production and IL-6 secretion
In order to induce an inflammatory response, similar to
that observed in many pathophysiological conditions,
LPS was used to stimulate the increase of iNOS and NO
as well as IL-6 release from a macrophage cell line. In
RAW264.7 macrophages, LPS (1 μg/ml) treatment
resulted in the increase of iNOS protein expression
starting from 1 h after initiation of treatment, whereas
NO release was detectable after 24 h of LPS-stimulation
(not shown). Co-treatment with AS101(2 μg/ml) mark-
edly reduced iNOS induction at 1 h (Fig. 1A-B) and 4 h
(Fig. 1C-D) after LPS stimulation vs LPS alone, while
AS101(0.5 μg/ml)+LPS did not cause significant changes
in iNOS expression vs LPS treated cells. To address
whether inhibition of iNOS was paralleled by a reduc-
tion in NO release, NO production was determined in
the form of nitrite in culture supernatants using the
Griess reagent. Unstimulated cells produced low levels
of NO2, while LPS stimulation considerably increased
the amounts of nitrite secreted in culture supernatants
(Fig. 1E). AS101 treatment of RAW264.7 cells signifi-
cantly inhibited LPS-stimulated NO production (Fig.
1E), whereas AS101 alone did not cause significant
changes in the NO levels. Moreover, LPS-induced IL-6
secretion was significantly down-regulated by AS101
treatment (Fig. 1F) while AS101 alone did not cause sig-
nificant changes in the IL-6 levels. These results imply
that AS101 may serve as anti-inflammatory agent
through down-regulation in iNOS and NO as well as in
IL-6 production. The protective anti-inflammatory cap-
abilities of AS101 prompted us to examine the mechan-
ism of action of this compound in our experimental
system.
AS101 down-regulates IKBa degradation and
phosphorylation via different kinetics
Since IKB proteins degradation is an essential step for
NFB activation and expression of its target iNOS gene
induced by LPS[2,20], AS101 effect on LPS-induced
IKBa degradation was examined. IKBa degradation was
detected with or without AS101 treatment 1 h after LPS
stimulation (Fig. 2A, C), while IKBa phosphorylation
(Fig. 2A, B) was not changed significantly in AS101 trea-
ted cells. Determination of IKBa degradation at 4 h after
LPS stimulation showed significant inhibition of IKBa
degradation in AS101 treated cells vs. those receiving
LPS treatment alone (Fig. 2D, F). Furthermore, detection
of IKBa phosphorylation revealed a clear inhibitory
effect on LPS-induced IKBa phosphorylation in the pre-
s e n c eo fA S 1 0 1( F i g .2 D ,E ) .T h i sd a t as u g g e s tt h a tt h e
tellurium compound, AS101, down-regulates iNOS
expression (Fig. 1) possibly through time dependent
kinetics. While at 4 h after LPS stimulation, AS101
treatment prevented IKBa degradation and phosphoryla-
tion, at 1 h after LPS stimulation, inhibition of iNOS
expression was observed in the presence of AS101 (Fig.
1), with no detection of inhibitory effect on IKBa degra-
dation and phosphorylation.
Effect of AS101 on LPS-induced NFkB translocalization
and p50 DNA-binding
Since p65 is a major component in the NFkB complex
activation, we examined p65 translocation to the
nucleus by immunoblotting (Fig. 3). RAW264.7 cells
were incubated with LPS in t h ep r e s e n c eo ra b s e n c eo f
AS101 for 1 h or 4 h. Translocation of p65 from the
cytosol into the nucleus was evident after 1 h in the pre-
sence of LPS, whereas LPS-stimulated AS101-treated
cells did not show significantc h a n g e sv sL P S( F i g .3 A -
B). At 4 h, LPS-activated cells demonstrated p65 trans-
location, while AS101 treatment abrogated this activity
(Fig. 3C-D).
Since iNOS transcription requires NFkB activation
through p50 DNA-binding to the indicated iNOS gene,
chromatin immunoprecipitation assay was carried out
using LPS-stimulated RAW264.7 extracts in the pre-
sence or absence of AS101. AS101 treatment attenuated
p50 DNA-binding abilities to the iNOS promoter region
in cells stimulated with LPS for 1 h (Fig. 4A-B). Collec-
tively, these data imply that although AS101 did not
inhibit NFkB nuclear translocation at 1 h, it prevented
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tor following LPS induction.
Discussion
In the present study, we attempted to elucidate the anti-
inflammatory effects of the tellurium compound, AS101.
We show that AS101 is an effective inhibitor of LPS-sti-
mulated iNOS expression and NO secretion in
RAW264.7 macrophages. The mechanism by which
AS101 inhibits the expression of these inflammatory
mediators appears to involve the NFkB pathway signal-
ing. Interestingly, IkB phosphorylation and degradation
and NFkB nuclear translocalization in LPS-stimulated
macrophages were affected by AS101 treatment at dif-
ferent kinetics when tested at 1 h vs 4 h. Furthermore,
AS101 treatment attenuated p50 subunit DNA-binding
abilities in the iNOS promoter. Furthermore, the secre-
tion of the inflammatory cytokine IL-6, regulated by the
NFkB pathway, was significantly inhibited by AS101.
These findings suggest that the tellurium compound,
Figure 1 Effect of AS101 on LPS-induced iNOS protein expression (A-D) and NO(E) and IL-6 (F) secretion. (A) LPS-stimulated RAW264.7
cells (1 × 10
6/ml) were treated with AS101(0.5 or 2 [μg/ml]) for 1 h (A) and 4 h (C). The iNOS level was analyzed by immunoblotting using anti-
iNOS. Actin was used as an internal loading control. Bar graphs represent the quantitative densitometric value of the expressed protein vs actin:
1 h (B) and 4 h (D). *p < 0.05 vs LPS. Data shown are representative of three different experiments. (E-F) LPS-stimulated RAW264.7 cells (1 × 10
6/
ml) were incubated with AS101 (2 μg/ml) for 24 h. The culture supernatants were subsequently isolated and analyzed for nitrite and IL-6 levels.
Data expressed as mean ± SE of four independent experiments. ** p < 0.05 vs. control, * p < 0.05 vs. LPS.
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mediated inflammatory genes.
The reactive free radical, NO, synthesized by iNOS is
a major macrophage-derived inflammatory mediator,
which is involved in various pathologies[21,22]. More-
over, it has been reported that IL-6 is a pro-inflamma-
tory cytokine, regarded as endogenous mediator of LPS-
induced fever[23]. AS101 treatment of LPS-activated
RAW264.7 macrophages resulted in the decrease of IL-6
production as well as in the down-regulation of iNOS
expression and NO secretion. NFB is known to play a
critical role in the regulation of cell survival genes and
coordination of pro-inflammatory mediators such as
iNOS and NO[2]. Therefore, the modulation of iNOS
expression by AS101 prompted us to examine the effect
of AS101 on this transcription complex activity. NFB
activation requires IKBa phosphorylation, which then
targets IKBa for ubiquitination and degradation [20].
Interestingly, IKBa phosphorylation and degradation fol-
lowed by NFkB nuclear translocalization was affected
differently by AS101 treatment, depending on the time
point studied. Thus, although AS101(2 μg/ml) inhibits
iNOS expression at both 1 h and 4 h (Fig. 1A, C), it
does not affect neither IKBa phosphorylation nor its
degradation at 1 h (Fig. 2A-C). Furthermore, NFkB
nuclear translocation was neither affected by AS101 at
that time point (Fig. 3A-B). Nevertheless, at 4 h, all
these processes were affected by AS101: the compound
both prevented IKBa phosphorylation and degradation
(Fig. 2D-F) and inhibited NFkB nuclear translocation
(Fig. 3C-D).
The molecular pathways involved in the regulation of
iNOS expression occur largely at a transcriptional level
and appear to be immensely heterogeneous, with parti-
cular mechanisms invoked in specific cell types[24].
However, a common signaling molecule involved in
these diverse pathways is the ubiquitous inflammatory
transcription factor, nuclear factor NFkB [24]. Based on
this evidence, and given the inhibitory effect of AS101
on NFkB activation at 4 h, the lack of modulation of the
NFkB pathway by AS101 at 1 h, concomitantly with the
inhibition of iNOS at that time point, prompted us to
further explore the mechanism of iNOS inhibition at 1
h. The results of the Chip assay revealed that treatment
with AS101 of LPS-stimulated RAW264.7 macrophages
attenuated p50-binding to the iNOS promoter region vs.
LPS treatment alone (Fig. 4).
Accumulated evidence suggests that much of the bio-
logical activity of organotellurium compounds is directly
related to their specific chemical interactions with
cysteine thiol residues. The Te(IV)-thiol chemical bond
may lead to conformational change or disulfide bond
formation in a specific protein, possibly resulting in the
loss of its biological activity, if the thiol residue is essen-
tial for that function. Indeed, we demonstrated that
AS101 and other TeIV-compounds specifically inactivate
Figure 2 Effect of AS101 on degradation and phosphorylation of IKBa in RAW264.7 macrophages. (A,D) Cells were treated with LPS in
the absence or in the presence of AS101 for 1 h (A) and 4 h (D). Total cellular proteins were prepared and immunoblotted using anti-pIKBa
ser32/
36, anti-IKBa and anti-actin. Bar graphs represent the quantitative densitometric value of the expressed protein vs actin: pIKBa
ser32/36 1 h (B) and
4 h (E), IKBa- 1 h (C) and 4 h (F). *p < 0.05 vs LPS. Data shown are representative of three different experiments.
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the other families of serine-, aspartic and metallopro-
teases, in good agreement with the predictions of their
unique Te(IV)-thiol chemistry. Furthermore, the proteo-
lytic activity of the inactivated cysteine proteases could
be restored by reducing agents further supporting the
suggestion that the inactivation process involves oxida-
tion of the catalytic thiol to a disulfide[14]. Furthermore,
neuroprotection exerted by AS101 in both Parkinson’s
disease models[16] and ischemic stroke[25] were shown
to be mediated by the Te(IV) redox chemistry of the
compound. Likewise, the protective mechanism of
AS101 against homocysteine toxicity was shown to be
directly mediated by its chemical reactivity, whereby
AS101 reacted with homocysteine to form homocystine,
the less toxic disulfide form of homocysteine[25]. These
Figure 3 Effect of AS101 on NFkB translocalization. LPS-stimulated RAW264.7 cells (1 × 10
6/ml) were treated with AS101 for 1 h (A) and 4 h
(C). Cytosolic and nuclear extracts were immunoblotted using anti-p65 of NFB and anti-actin. Extracts were immunoblotted using RCC1
indicating nuclear purity of the fractions (not shown). Bar graphs represent the quantitative densitometric value of the expressed protein vs
actin: p65 1 h (B) and 4 h (D). *p < 0.05 vs LPS. Data shown are representative of three different experiments.
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aforementioned anti-inflammatory effects of the
compound.
The critical step in NF-kB activation is IkBa phos-
phorylation at Ser32 and Ser36 by IkB kinase complex
[26] while both IKKs contain a cysteine at 179 in their
activation loop. Based on the evidence that NFBh a sa
well-conserved cysteine residue in its p50-subunit
together with location of NFB recognition consensus-
binding site in the iNOS promoter - modulation of
NFB activity may be carried out by redox regulation in
a great part through a decrease in DNA-binding activity
due to redox-sensitive cysteine residues[27,28].
Thus, the effect of AS101 in our experimental system
may be mediated by inhibition of two steps in the NFB
pathway by modifying specific cysteine residues in IKKa
and in the p50-subunit resulting in the inhibition of
nuclear translocation and DNA-binding to the iNOS
promoter. Nevertheless these effects are exerted at dif-
ferent kinetics. I. At 1 h, AS101 probably enters the
nucleus and may interfere with the DNA-binding ability
of the NFB complex resulting in the inhibition of
iNOS expression. Because tellurium readily forms com-
plexes such as Rs-Te-SR or Rs-Te with reactive sulfhy-
dryl groups in proteins, such derivatives could account
for the observed inhibition of p50-binding to its DNA
targets by the reactive tellurium compound. II. At 4 h
inhibition of iNOS expression by AS101 may be attribu-
ted to the compound’s activity in the cytosol inhibiting
IKKa phosphorylation, degradation and NFBn u c l e a r
translocation.
The NFB complex functions as a key factor in
inflammation. AS101 treatment inhibits NFB activities
and thereby acts as an anti-inflammatory agent in NFB
target genes such as iNOS and NO formation as well as
IL-6 production. Moreover, AS101 has been shown to
have therapeutic effects in various experimental animal
models without obvious side effects and has shown
excellent safety profile in human clinical trials. The
investigation of therapeutic activities of tellurium com-
pounds is scarce in the literature, despite the relative
abundance of tellurium in the human body. Over the
last decade, there has been an increased appreciation for
the role of redox chemistry in the regulation of biologi-
cal systems. Understanding the mechanism of thiol
modifying tellurium compounds such as AS101, cur-
rently used in phase II/III clinical trials, that blocks mul-
tiple steps in the NFB signaling pathway, may lead to
the development of more effective therapies for inflam-
matory diseases.
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